BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 29869425)

  • 1. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need.
    Pereira MP; Basta S; Moore J; Ständer S
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2224-2229. PubMed ID: 29869425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prurigo Nodularis Management.
    Tsianakas A; Zeidler C; Ständer S
    Curr Probl Dermatol; 2016; 50():94-101. PubMed ID: 27578077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
    Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
    JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.
    Williams KA; Roh YS; Brown I; Sutaria N; Bakhshi P; Choi J; Gabriel S; Chavda R; Kwatra SG
    Expert Rev Clin Pharmacol; 2021 Jan; 14(1):67-77. PubMed ID: 33191806
    [No Abstract]   [Full Text] [Related]  

  • 5. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus.
    Elmariah S; Kim B; Berger T; Chisolm S; Kwatra SG; Mollanazar N; Yosipovitch G
    J Am Acad Dermatol; 2021 Mar; 84(3):747-760. PubMed ID: 32682025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical review of dupilumab for adult patients with prurigo nodularis.
    Biazus Soares G; Yosipovitch G
    Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo.
    Pereira MP; Steinke S; Zeidler C; Forner C; Riepe C; Augustin M; Bobko S; Dalgard F; Elberling J; Garcovich S; Gieler U; Gonçalo M; Halvorsen JA; Leslie TA; Metz M; Reich A; Şavk E; Schneider G; Serra-Baldrich E; Ständer HF; Streit M; Wallengren J; Weller K; Wollenberg A; Bruland P; Soto-Rey I; Storck M; Dugas M; Weisshaar E; Szepietowski JC; Legat FJ; Ständer S;
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1059-1065. PubMed ID: 28857299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
    Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
    N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Prurigo of Nodular Type: A Review.
    Zeidler C; Tsianakas A; Pereira M; Ständer H; Yosipovitch G; Ständer S
    Acta Derm Venereol; 2018 Feb; 98(2):173-179. PubMed ID: 29135018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INDIVIDUAL ARTICLE: Management of Prurigo Nodularis.
    Elmariah SB; Tao L; Valdes-Rodriguez R; Laquer V
    J Drugs Dermatol; 2023 Dec; 22(12):SF365502s15-SF365502s22. PubMed ID: 38051855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
    Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
    EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and disease burden in prurigo nodularis.
    Aggarwal P; Choi J; Sutaria N; Roh YS; Wongvibulsin S; Williams KA; Huang AH; Boozalis E; Le T; Chavda R; Gabriel S; Kwatra SG
    Clin Exp Dermatol; 2021 Oct; 46(7):1277-1284. PubMed ID: 33969517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Position Statement: Linear prurigo is a subtype of chronic prurigo.
    Pereira MP; Zeidler C; Nau T; Bobko S; Evers AWM; Garcovich S; Gonçalo M; Halvorsen JA; Lambert J; Legat FJ; Leslie T; Metz M; Misery L; Nordlind K; Reich A; Schneider G; Ständer H; Streit M; Szepietowski JC; Wallengren J; Weisshaar E; Ständer S;
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):263-266. PubMed ID: 30288812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide for the treatment of chronic refractory prurigo nodularis.
    Aguh C; Kwatra SG; He A; Okoye GA
    Dermatol Online J; 2018 Mar; 24(3):. PubMed ID: 29634881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Psychosomatic aspects of prurigo nodularis].
    Schneider G; Hockmann J; Stumpf A
    Hautarzt; 2014 Aug; 65(8):704-8. PubMed ID: 25113329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis.
    Janmohamed SR; Gwillim EC; Yousaf M; Patel KR; Silverberg JI
    Arch Dermatol Res; 2021 Oct; 313(8):669-677. PubMed ID: 33108524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
    Fang HY; Lian CH
    J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of dupilumab in prurigo nodularis in elderly patient.
    Giura MT; Viola R; Fierro MT; Ribero S; Ortoncelli M
    Dermatol Ther; 2020 Jan; 33(1):e13201. PubMed ID: 31856368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.
    Deng J; Liao V; Parthasarathy V; Cornman HL; Kambala A; Kwatra MM; Ständer S; Piketty C; Chaskar P; Krishnaswamy JK; Julia V; Kwatra SG
    JAMA Dermatol; 2023 Sep; 159(9):977-985. PubMed ID: 37556125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial.
    Steinke S; Zeidler C; Riepe C; Bruland P; Soto-Rey I; Storck M; Augustin M; Bobko S; Garcovich S; Legat FJ; Lvov A; Misery L; Osada N; Reich A; Şavk E; Serra-Baldrich E; Streit M; Szepietowski JC; Weger W; Dugas M; Ständer S
    J Am Acad Dermatol; 2018 Sep; 79(3):457-463.e5. PubMed ID: 30119869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.